RESUMO
A medicated plaster containing diclofenac epolamine (DHEP) and heparin has been recently proposed for the treatment of local trauma (ie, ankle sprains) accompanied by a clinically significant edema and/or hematoma formation, based on the combined antiinflammatory, hemorheologic, and antiedema properties of diclofenac and heparin. The aim of this study was therefore to compare the effects of a combined DHEP/heparin and DHEP alone in 2 clinical experimental models of microangiopathy, in order to provide a pharmacologic rationale for association of diclofenac and heparin. The microcirculation was evaluated by measuring cutaneous blood flow (laser Doppler) and transcutaneous oxygen and carbon dioxide pressures (TcPO(2) and TcPCO(2)) in 10 healthy volunteers before and after producing 2 microcirculatory models of microangiopathy: the models were based on reactive hyperemia (RH) and on local histamine injection, which both produce a significant increase in skin flux and alterations of TcPO(2) and TcPCO(2). The area of the study was the distal medial leg, treated with placebo, DHEP alone (Flector Tissugel), and DHEP/heparin (Flector Tissugel Heparin). The plasters were applied before producing the microcirculatory models to evaluate the efficacy of DHEP and DHEP/heparin in controlling and limiting vasodilatation and development of microangiopathy. A significant increase in cutaneous flux was obtained with both models. The application of DHEP partially limited the increase in flux and in TcPCO(2), as well as the decrease in TcPO(2) (which were considered signs of microangiopathy), but the combination DHEP/heparin was significantly more effective than DHEP alone. The inclusion of heparin in the plaster thus improved the control of the microcirculation achieved with diclofenac alone, when an experimental model of venous/arterial hyperemia and microangiopathy was used. In conclusion, DHEP in association with heparin modulates microcirculatory changes better than DHEP alone. It should be interesting to investigate the product in comparable clinical conditions in which it may be useful to act pharmacologically both on inflammation and microcirculatory disturbances that delay the recovery of patients.
Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Anticoagulantes/administração & dosagem , Diclofenaco/administração & dosagem , Heparina/administração & dosagem , Doenças Vasculares Periféricas/tratamento farmacológico , Doenças Vasculares Periféricas/fisiopatologia , Adulto , Moldes Cirúrgicos , Quimioterapia Combinada , Feminino , Humanos , Perna (Membro)/irrigação sanguínea , Masculino , Microcirculação/fisiopatologia , Pessoa de Meia-Idade , Modelos CardiovascularesRESUMO
Acetylcholine release was investigated in cortical slices superfused with choline-enriched Krebs solution containing physostigmine. Slices were prepared from 3 and 24 month old rats treated with either Tris buffer or sonicated suspensions of phosphatidylserine and phosphatidylcholine in Tris buffer. Slices were electrically stimulated at frequencies of 1, 2 and 5 Hz for 5 min periods preceded and followed by rest periods. ACh content of the superfusate was quantified by bioassay. In the 24 month old rats treated with Tris buffer, acetylcholine release, at all frequencies tested, was approximately 50% lower than that in the 3 month old rats. On the contrary, no significant decrease in ACh release was found in the 24 month old rats treated for 30 days with phosphatidylserine (15 mg/kg IP). The same treatment did not increase acetylcholine release in 3 month old rats. Acetylcholine release in 24 month old rats receiving a single administration of phosphatidylserine (15 mg/kg IP) or phosphatidylcholine (15 mg/kg IP) for 30 days was as low as in the 24 month old rats receiving the Tris buffer only. It is proposed that the chronic phosphatidylserine treatment may reduce the age-induced decrease in acetylcholine release by acting on the stimulus-secretion coupling mechanism.
Assuntos
Acetilcolina/metabolismo , Envelhecimento , Córtex Cerebral/metabolismo , Fosfatidilserinas/farmacologia , Animais , Estimulação Elétrica , Técnicas In Vitro , Masculino , Fosfatidilcolinas/farmacologia , Ratos , Ratos Endogâmicos , Estimulação QuímicaRESUMO
The effect of caffeine and aminophylline on the release of acetylcholine (ACh) was investigated in slices of rat cortex perfused with Krebs solution at rest and during electrical stimulation at frequencies of 0.2, 1 and 5 Hz. Both methylxanthines added to the superfusing Krebs solution at a concentration of 50 microM enhanced ACh release. Conversely, at a concentration of 0.5 mM both caffeine and aminophylline decreased ACh release. Neither caffeine nor aminophylline affected the unstimulated ACh release. Dipyridamole 10 microM potentiated the inhibitory effect of adenosine 30 microM on ACh release and antagonized both the stimulatory and inhibitory effects of caffeine on ACh release. The inhibitory effect of caffeine was antagonized by cyclohexyladenosine (CHA) 0.5 microM and N-ethylcarboxamideadenosine (NECA) 5 microM. The results indicate that methylxanthines exert both stimulatory and inhibitory effects on ACh release by acting on adenosine receptors. Methylxanthines may enhance the electrically-evoked ACh release by antagonizing the effect of endogenous adenosine on inhibitory adenosine receptors. On the other hand the mechanism through which methylxanthines decrease ACh release remains obscure.
Assuntos
Acetilcolina/metabolismo , Encéfalo/metabolismo , Xantinas/farmacologia , Adenosina/análogos & derivados , Adenosina/farmacologia , Aminofilina/farmacologia , Animais , Encéfalo/efeitos dos fármacos , Cafeína/farmacologia , Dipiridamol/farmacologia , Interações Medicamentosas , Estimulação Elétrica , Técnicas In Vitro , Masculino , Ratos , Ratos EndogâmicosRESUMO
Intracerebroventricular administration (6 micrograms/2 microliters) of D-2-amino-5-phosphonovalerate (AP-5), a specific antagonist of the NMDA receptors, prior to training impaired the passive avoidance in a retention test in rat. Pretreatment with oxiracetam and D-pyroglutamic acid at doses ranging from 50 to 500 mg/kg SC dose-dependently prevented the disruptive effect of AP-5. This finding indicates that an interaction with excitatory amino acid NMDA type receptors may be important in behavioural effects of the two pyrrolidinone derivatives.
Assuntos
Aprendizagem da Esquiva/efeitos dos fármacos , Pirrolidinas/farmacologia , Pirrolidinonas/farmacologia , Ácido Pirrolidonocarboxílico/farmacologia , Receptores de Neurotransmissores/efeitos dos fármacos , Valina/análogos & derivados , Animais , Injeções Intraventriculares , Masculino , Atividade Motora/efeitos dos fármacos , Ratos , Ratos Endogâmicos , Receptores de N-Metil-D-Aspartato , Valina/antagonistas & inibidores , Valina/farmacologiaRESUMO
In the rat, 1 min following electroshock (ECS) a 46 and 39% decrease in acetylcholine levels was found in the hippocampus and cerebral cortex, respectively. The decrease in the hippocampus was still statistically significant 30 min after ECS. The ECS applied 1 min after training also disrupted the performance of a passive avoidance conditioned response ('step down') tested 30 min later. Oxiracetam (100 and 300 mg/kg i.p.) administered 90 min before training prevented, in a dose-dependent manner, the decrease of acetylcholine in the cerebral cortex and hippocampus. Oxiracetam prevented the ECS disruption of the acquisition of a passive avoidance response. At the dose of 300 mg/kg the acetylcholine level 1 min after ECS was significantly higher than in the sham-treated rats. Piracetam at the same doses was inactive. These results support the hypothesis that oxiracetam may prevent the disruption of the conditioned response by acting on cortical and hippocampal cholinergic mechanisms.
Assuntos
Acetilcolina/metabolismo , Amnésia/prevenção & controle , Encéfalo/efeitos dos fármacos , Pirrolidinas/farmacologia , Amnésia/etiologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Encéfalo/metabolismo , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Colina/metabolismo , Eletrochoque , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Masculino , Piracetam/farmacologia , Ratos , Ratos EndogâmicosRESUMO
G 619 is 3-carbamyl-(3'-picolyl)-4-methoxy-1-benzamide. The compound is structurally related to picotamide, a previously reported dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist, which displays inhibitory activity on tumor necrosis factor-alpha. The aim of the present work was to study the effect of G 619 on tumor necrosis factor-alpha synthesis both in vivo and in vitro. Salmonella enteritidis lipopolysaccharide was used to induce tumor necrosis factor-alpha production. Septic shock was produced in male rats by a single intravenous (i.v.) injection of 20 mg/kg (LD90) of Salmonella enteritidis lipopolysaccharide. Rats were pretreated with G 619 (50 mg/kg, i.v.) or vehicle (1 ml/kg, i.v.) 1 h before endotoxin challenge. Salmonella enteritidis lipopolysaccharide administration dramatically reduced survival rate (0%, 72 h after endotoxin administration), reduced mean arterial blood pressure, increased plasma levels of thromboxane B2 and 6-keto-prostaglandin F1 alpha and enhanced serum levels of tumor necrosis factor. Furthermore, endotoxic shock produced characteristic gastric damage, consisting of haemorrhagic infiltrates. Pretreatment with G 619 in vivo significantly protected against Salmonella enteritidis lipopolysaccharide-induced lethality (80% survival rate and 60% survival rate 24 h and 72 h after Salmonella enteritidis lipopolysaccharide injection, respectively), reduced hypotension, decreased plasma thromboxane B2 and serum tumor necrosis factor-alpha levels and enhanced blood levels of 6-keto-prostaglandin F1 alpha. In rat peritoneal macrophages, G 619 in vitro (25, 50 and 100 microM) significantly blunted (P < 0.001) Salmonella enteritidis lipopolysaccharide-stimulated production of tumor necrosis factor-alpha, whereas it increased 6-keto-prostaglandin F1 alpha and cyclic AMP levels. The present data indicate that G 619 may be useful during disease states characterized by elevated tumor necrosis factor-alpha levels.
Assuntos
Benzamidas/farmacologia , Picolinas/farmacologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , 6-Cetoprostaglandina F1 alfa/sangue , Animais , AMP Cíclico/análise , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/patologia , Lipopolissacarídeos , Macrófagos Peritoneais/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley , Receptores de Tromboxanos/antagonistas & inibidores , Salmonella enteritidis , Choque Séptico/induzido quimicamente , Choque Séptico/prevenção & controle , Tromboxano B2/sangue , Tromboxano-A Sintase/antagonistas & inibidores , Fator de Necrose Tumoral alfa/análiseRESUMO
1. This review has two aims: first, to marshal and discuss evidences demonstrating an interaction between nootropic drugs and brain cholinergic mechanisms; second, to define the relationship between the effects on cholinergic mechanisms and the cognitive process. 2. Direct or indirect evidences indicating an activation of cholinergic mechanisms exist for pyrrolidinone derivatives including piracetam, oxiracetam, aniracetam, pyroglutamic acid, tenilsetam and pramiracetam and for miscellaneous chemical structures such as vinpocetine, naloxone, ebiratide and phosphatidylserine. All these drugs prevent or revert scopolamine-induced disruption of several learning and memory paradigms in animal and man. 3. Some of the pyrrolidinone derivatives also prevent amnesia associated with inhibition of acetylcholine synthesis brought about by hemicholinium. Oxiracetam prevents the decrease in brain acetylcholine and amnesia caused by electroconvulsive shock. Oxiracetam, aniracetam and pyroglutamic acid prevent brain acetylcholine decrease and amnesia induced by scopolamine. Comparable bell-shaped dose-effect relationships result for both actions. Phosphatidylserine restores acetylcholine synthesis and conditioned responses in aging rats. 4. The mechanisms through which the action on cholinergic systems might take place, including stimulation of the high affinity choline uptake, are discussed. The information available are not yet sufficient to define at which steps of the cognitive process the action on cholinergic system plays a role and which are the influences of the changes in cholinergic function on other neurochemical mechanisms of learning and memory.
Assuntos
Acetilcolina/metabolismo , Encéfalo/metabolismo , Psicotrópicos/farmacologia , Animais , Encéfalo/efeitos dos fármacos , Receptores Colinérgicos/efeitos dos fármacos , Receptores Colinérgicos/metabolismo , Escopolamina/farmacologia , Sinapses/efeitos dos fármacos , Sinapses/fisiologiaRESUMO
Pyroglutamic acid (PCA) was compared with placebo in a randomized, double blind trial for assessing its efficacy in treating memory deficits in 40 aged subjects. Twenty subjects were treated with PCA and 20 with placebo over a period of 60 d. Memory functions were evaluated at baseline and after 60 d of treatment by means of a battery made up of 6 memory tasks. The results suggest that PCA is effective in improving some verbal memory functions in subjects affected by age-related memory decline.
Assuntos
Transtornos da Memória/tratamento farmacológico , Pirrolidinonas/uso terapêutico , Ácido Pirrolidonocarboxílico/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Percepção de Forma/efeitos dos fármacos , Humanos , Transtornos da Memória/psicologia , Pessoa de Meia-Idade , Desempenho Psicomotor/efeitos dos fármacos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Oxiracetam at 100 and 300 mg/kg i.p. dose levels increased acetylcholine (ACh) utilization in the rat cerebral cortex and hippocampus. ACh utilization was assessed by measuring, with a gas chromatographic method, the decrease in ACh level after inhibiting its synthesis by 15 micrograms intracerebroventricularly (i.c.v.) injection of hemicholinium (HC-3). ACh steady state levels were not affected. Piracetam (300 mg/kg i.p.) also increased ACh utilization in the hippocampus. Repeated daily administration of oxiracetam 100 mg/kg i.p. caused a 31% increase in high-affinity choline uptake (HACU) in the hippocampus. A single administration of 300 mg/kg i.p. of oxiracetam and piracetam also increased HACU rate in the hippocampus. However, the effect of piracetam was over within 3 h, while 3 h after its administration oxiracetam still caused a 40% increase in HACU rate. Oxiracetam (100 mg/kg i.p.) significantly antagonized the impairment in the acquisition of an active-avoidance conditioned response (pole climbing) associated with the inhibition of ACh synthesis by HC-3. These results indicate that oxiracetam enhances the activity of the septohippocampal cholinergic pathways, and to a lesser extent, of the cortical cholinergic network.
Assuntos
Acetilcolina/metabolismo , Aprendizagem da Esquiva/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Piracetam/farmacologia , Pirrolidinas/farmacologia , Pirrolidinonas/farmacologia , Animais , Córtex Cerebral/metabolismo , Colina/metabolismo , Corpo Estriado/metabolismo , Hemicolínio 3/farmacologia , Hipocampo/metabolismo , Masculino , Ratos , Ratos EndogâmicosRESUMO
The effect of cognition-enhancing agents oxiracetam and aniracetam on scopolamine-induced amnesia and brain acetylcholine decrease was investigated in the rat. Acetylcholine levels were measured by means of a gas-chromatographic method. Scopolamine (0.63 mg/kg IP 60 min before training) prevented the acquisition of a passive avoidance conditioned response ("step through": retest 30 min after training) and brought about a 64, 56 and 42% decrease in acetylcholine level in the cortex, hippocampus and striatum respectively. Oxiracetam (50 and 100 mg/kg IP) administered 30 min before scopolamine reduced the scopolamine-induced amnesic effect and decrease in acetylcholine level in the cortex and hippocampus, but not in the striatum. Lower and higher doses of oxiracetam were ineffective. Aniracetam (100 mg/kg PO) also prevented scopolamine-induced amnesia but attenuated acetylcholine decrease in the hippocampus only. Aniracetam (300 mg PO) reduced acetylcholine decrease in the hippocampus but did not prevent scopolamine-amnesia. In conclusion, oxiracetam and aniracetam exert a stimulatory effect on specific central cholinergic pathways. However, a direct relationship between cognition-enhancing properties and cholinergic activation needs further confirmation.
Assuntos
Acetilcolina/análise , Aprendizagem da Esquiva/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Pirrolidinas/farmacologia , Pirrolidinonas/farmacologia , Escopolamina/farmacologia , Animais , Encéfalo/metabolismo , Encéfalo/fisiologia , Química Encefálica/efeitos dos fármacos , Masculino , Ratos , Ratos Endogâmicos , Tempo de Reação/efeitos dos fármacosRESUMO
The in-vitro activities of two new miconazole and econazole salts (sulfosalicylic acid formulation) against 98 clinical isolates of dermatophytes were evaluated, in comparison to those of miconazole, miconazole nitrate, econazole and econazole nitrate. Miconazole sulfosalicylate and econazole sulfosalicylate exhibited good activity towards all the dermatophytes tested, although econazole and its derivatives were more efficacious than miconazole and its salts. The new imidazoles were equally effective in inhibiting the fungal growth with respect to miconazole, miconazole nitrate, econazole and econazole nitrate.
Assuntos
Antifúngicos/farmacologia , Arthrodermataceae/efeitos dos fármacos , Miconazol/análogos & derivados , Miconazol/farmacologia , Humanos , Testes de Sensibilidade MicrobianaRESUMO
The aim of this investigation was to compare the contact action of econazole sulfosalicylate (E-SSA) on mycetes (Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Trichophyton rubrum, T. cutaneum, Pityrosporum sp.), Gram-positive bacteria (Staphylococcus aureus, Streptococcus faecalis) and Gram-negative bacteria (Escherichia coli, Citrobacter freundii) with that exerted by econazole nitrate (E-NIT). The results show E-SSA activity greater than E-NIT (in particular against mycetes and Gram-negative bacteria). The E-SSA contact activity trials illustrated certain properties of this imidazole sulfosolicylate such as: absence of latency time, antimicrobial activity proportional to its concentration, when a high concentration is used, given the limiting influence of pH and ionic strength of the medium. The higher E-SSA contact activity, in relation to E-NIT, can be correlated to its greater lipophylia considering also the lipophylic properties of SSA and the scarce dissociation of E-SSA.
Assuntos
Econazol/análogos & derivados , Econazol/farmacologia , Aspergillus fumigatus/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Cryptococcus neoformans/efeitos dos fármacos , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Testes de Sensibilidade Microbiana , Fungos Mitospóricos/efeitos dos fármacosRESUMO
The two stereoisomers of pyroglutamic acid (PCA), a nootropic or cognition-enhancing agent, and classic reference compounds were investigated for their ability to interact with 27 neurotransmitter receptors and drug binding sites prepared from selected areas of the central nervous system and labelled with high affinity and selectivity with specific radioligands. L-PCA significantly interacted with the rat forebrain excitatory amino acid receptors labelled with 3H-L-glutamic acid. The IC50 of L-PCA was 28.11 microM, that of cold L-glutamic acid was 1.68 microM. The corresponding figure for L-aspartic acid was 16.95 microM. The indirect Hill plot gave coefficients of 0.48, 1.08 and 0.75 for L-PCA, L-glutamic and L-aspartic acids, respectively. Only very high concentrations (10(-4) M) of L-PCA were able to slightly antagonize the specific binding of 3H-clonidine to alpha 2-adrenergic receptors, of 3H-dihydroalprenolol to beta 1- and beta 2-adrenergic receptors of the heart and of the lung and of 3H-diazepam to benzodiazepine receptors. The D-isomer of PCA was practically as active as the L-isomer on these receptors. Finally, L-PCA (10(-5) to 10(-4) M) was unable to antagonize the specific binding of all the other radioligands to their respective receptors and binding sites. D-PCA did not significantly interact with excitatory amino acid receptors or with any of the other sites studied here.
Assuntos
Pirrolidinonas/metabolismo , Ácido Pirrolidonocarboxílico/metabolismo , Animais , Sítios de Ligação , Encéfalo/metabolismo , Bloqueadores dos Canais de Cálcio/metabolismo , Canais de Cloreto , Clonidina/antagonistas & inibidores , Diazepam/metabolismo , Relação Dose-Resposta a Droga , Glutamatos/metabolismo , Ácido Glutâmico , Cobaias , Masculino , Proteínas de Membrana/metabolismo , Mianserina/metabolismo , Ratos , Receptores Adrenérgicos/metabolismo , Receptores Adrenérgicos alfa/metabolismo , Receptores Adrenérgicos beta/metabolismo , Receptores de Aminoácido , Receptores de Superfície Celular/metabolismo , Receptores Colinérgicos/metabolismo , Receptores Dopaminérgicos/metabolismo , Receptores de GABA-A/metabolismo , Receptores de Glutamato , Receptores de Glicina , Receptores Histamínicos/metabolismo , Receptores Muscarínicos/metabolismo , Receptores de Neurotransmissores/metabolismo , Receptores Opioides/metabolismo , Receptores Purinérgicos/metabolismo , Receptores de Serotonina/metabolismo , EstereoisomerismoAssuntos
Encéfalo/efeitos dos fármacos , Cognição/efeitos dos fármacos , Sistema Nervoso Parassimpático/efeitos dos fármacos , Pirrolidinas/farmacologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Fenômenos Biomecânicos , Encéfalo/fisiologia , Condicionamento Psicológico/efeitos dos fármacos , Masculino , Sistema Nervoso Parassimpático/fisiologia , Ratos , Ratos Endogâmicos , Escopolamina/antagonistas & inibidores , Escopolamina/farmacologiaAssuntos
Acetilcolina/metabolismo , Envelhecimento , Córtex Cerebral/efeitos dos fármacos , Transtornos Cognitivos/tratamento farmacológico , Fosfatidilserinas/farmacologia , Pirrolidinas/farmacologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Córtex Cerebral/análise , Córtex Cerebral/metabolismo , Corpo Estriado/análise , Hipocampo/análise , Ratos , Escopolamina/antagonistas & inibidores , Escopolamina/farmacologia , Taxa Secretória/efeitos dos fármacosRESUMO
The acquisition of a passive avoidance conditioned response was disrupted in the rat by electroconvulsive shock (ECS) and scopolamine administration. D,L-pyroglutamic acid (D,L-PCA) 500 and 1000 mg/kg, administered as arginine salt 120 min before the retest, prevented both the ECS and scopolamine-induced amnesia. Arginine alone was ineffective. Scopolamine brought about a 52 and 39% decrease, respectively, in cortical and hippocampal acetylcholine (ACh) levels, measured by means of a gas-chromatographic method. D,L-PCA 500 and 1000 mg/kg also prevented the decrease in brain ACh level. When the two isomers were studied separately, D-PCA was more effective than L-PCA and antagonized scopolamine-induced amnesia at the doses of 250 and 500 mg/kg. In conclusion, D,L-PCA is active on cortical and hippocampal cholinergic mechanisms and, like other 2-oxopyrrolidone derivatives, shows cognition-enhancing properties.